Figure 1
Figure 1. Cumulative incidence of neutrophil and platelet engraftment after MA URD-PBSC transplantation by CD34+ dose. CD34+ cell doses higher than 3.8 × 106/kg recipient weight improved neutrophil and platelet engraftment compared with lower doses (P = .025 for neutrophil engraftment at 25 days; P < .001 for platelet engraftment > 50000/μL at 60 days). ANC indicates neutrophil engraftment; PLT, platelet engraftment; Low, no more than 3.8 × 106 CD34+/kg (n = 107, ANC; n = 106, PLT); High, greater than 3.8 × 106 CD34+/kg (n = 327, ANC; n = 324, PLT).

Cumulative incidence of neutrophil and platelet engraftment after MA URD-PBSC transplantation by CD34+ dose. CD34+ cell doses higher than 3.8 × 106/kg recipient weight improved neutrophil and platelet engraftment compared with lower doses (P = .025 for neutrophil engraftment at 25 days; P < .001 for platelet engraftment > 50000/μL at 60 days). ANC indicates neutrophil engraftment; PLT, platelet engraftment; Low, no more than 3.8 × 106 CD34+/kg (n = 107, ANC; n = 106, PLT); High, greater than 3.8 × 106 CD34+/kg (n = 327, ANC; n = 324, PLT).

Close Modal

or Create an Account

Close Modal
Close Modal